Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. How to Estimate QT Interval in Patients With Left or Right Bundle Branch Block: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Severe Parkinsonism and Creatine Kinase Increase After Low-Dose Aripiprazole Treatment in a Patient of African Descent

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Off-Label Prescription of Psychopharmacological Drugs in Child and Adolescent Psychiatry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Norquetiapine and Depressive Symptoms in Initially Antipsychotic-Naive First-Episode Schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. An observational study of emotion regulation in children with Tourette syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Søvnforstyrrelser hos børn og unge

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Selvmordsforebyggende klinikker for børn og unge med fokus på Region Hovedstaden

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders. However, the evidence of its use in children and adolescents is rather sparse. The aim of this case study is to discuss adverse drug reaction (ADR) reports concerning aripiprazole-associated neurological and psychiatric events in children and adolescents. The ADR report database at Danish Medicines Agency was searched for all ADRs involving children and adolescents (<18 years) reported by the search term [aripiprazole] AND all spontaneous reports since the introduction of aripiprazole in 2003 until December 31, 2015. Nineteen case reports were included in the study and included both patients with psychotic disorders (PS group) and nonpsychotic disorders (non-PS group). The PS group consisted of 5 patients with schizophrenia and psychoses, not otherwise specified; and the non-PS group consisted of fourteen cases including autism spectrum disorders, attention deficit and hyperactivity disorder, obsessive-compulsive disorder, and Tourette syndrome. The main reported adverse effects in the non-PS group were chronic insomnia, Parkinsonism, behavioral changes psychoses, and weight gain, whereas the adverse effects in the PS group was predominantly anxiety, convulsions, and neuroleptic malignant syndrome. Although aripiprazole is considered safe and well tolerated in children and adolescents, severe adverse events as neuroleptic malignant syndrome, extreme insomnia, and suicidal behavior has been reported to health authorities. Clinicians should pay attention to these possible hazards when prescribing aripiprazole to this vulnerable group of patients.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Psychopharmacology
Vol/bind36
Udgave nummer5
Sider (fra-til)496-9
Antal sider3
ISSN0271-0749
DOI
StatusUdgivet - okt. 2016

ID: 48332750